Reltecimod (AB-103) is a T-cell-specific surface glycoprotein CD28 (TP44) antagonist. Reltecimod has beneficial effects against different bacterial infections, their exotoxins and endotoxins, and ionizing radiation. Reltecimod modulates the inflammatory response by targeting and attenuating the critical CD28/B7-2 co-stimulatory pathway, without inhibiting it. Reltecimod can be used to research necrotizing soft-tissue infections (NSTIs)[1][2].
Molecular Weight:
1037.19
Purity:
99.88
CAS Number:
[1447799-33-8]
Formula:
C46H72N10O15S
Target:
Bacterial,CD28
Application Notes:
Peptides
* VAT and and shipping costs not included. Errors and price changes excepted
